EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Emyria Ltd (EMD) fair value: what the stock is really worth

We calculate from audited financials what Emyria Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · AU · ISIN AU0000073645

EL Thin data Jun 24, 2026

Emyria Ltd

EMD · AU

Weakest SetupStrongly overvalued and low quality.

!Fair value A$0.0255 · Strongly overvalued (−50%)
!Quality 39/100
!Weak Growth (revenue 5y +6.6 %/yr)
!Loss-making · -198.5% net margin (TTM)
!negative free cash flow
!Trails peers (1/9)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Emyria Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.4950 A$0.0230 Fair Value A$0.0255 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.

How to read this chart

60‑month range A$0.0230 – A$0.4950 · fair‑value band A$0.0170 – A$0.0340 · the A$0.0510 price screens above the A$0.0255 fair value. Dashed = 300-day average. As of Jun 24, 2026.

Follow Emyria in your weekly email

Every Wednesday you see whether Emyria is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression.

Show more

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.

Stock analysis

Emyria Ltd (EMD) currently trades at A$0.0510, while our model-based Fair Value estimate is A$0.0255, implying the stock looks roughly 100.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 4 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: A$0.0170 (bear) to A$0.0340 (bull), the price of A$0.0510 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Emyria Ltd reported revenue of A$1.4M in FY2025 versus A$2.0M in FY2021, a compound −8.3%/yr. Reported net income was −A$3.1M in FY2025.

Key figures

Market cap A$32.3M (≈ $22.7M) · P/S ratio 14.1 · EPS (TTM) A$−0.0100 · Net margin −199% · Return on equity −58.7% · Return on assets (EBIT) −80.8% · Operating margin −126% · Revenue (TTM) A$2.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −50%, EMD screens richer than that median.

Fair Value models

Bear A$0.0170 Fair Value A$0.0255 Bull A$0.0340
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) n/a n/a A$0.0100 48
All 1 models by family
Asset-Based
NCAV (Graham) n/a n/a A$0.0100 48

Open the full fair value analysis →

Notify me when EMD reaches fair value

Put EMD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 39/100

Of which business quality 41 · Market factors (momentum, volatility) 51

Profitability 1
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 98
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 62
Price trend over the last 3–12 months (market factor)
52W Momentum 32
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 11/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−36.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−555.6% (2020) → −189.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EMD screens 100% overvalued. Compare with Veeva Systems Inc →

Compare Emyria Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 134 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −45% · Below median
Profitability
Return on assets −26% · Bottom 25%
Net margin (TTM) −199% · Bottom 25%
Operating margin (TTM) −126% · Bottom 25%
Growth and dividend
Revenue growth 136% · Top 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 4.28× · Priciest 25%
P/S (TTM) 9.91× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 3
FUTURE (revenue growth)100 · sector 34
PAST (return on equity)0 · sector 5
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 48

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $260.91 $287.00 +10%
Pro Medicus Limited PME A$161.31 A$64.50 −60%
BrightSpring Health Services, Inc BTSG $56.55 $26.07 −54%
HealthEquity, Inc HQY $91.75 $100.93 +10%
Hinge Health, Inc HNGE $94.15 $51.66 −45%
10x Genomics, Inc TXG $80.70 $21.71 −73%
Waystar Holding WAY $25.63 $28.19 +10%
XtalPi Holdings 2228 HK$8.39 HK$1.50 −82%
Doximity, Inc DOCS $26.51 $31.41 +18%
Privia Health Group PRVA $19.46 $5.26 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Emyria Ltd · Fair Value
A$0.0255 −100%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Emyria Ltd Fair Value". https://www.fairvalue-calculator.com/stock/EMD

Frequently asked questions

Is Emyria Ltd (EMD) overvalued or undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$0.0255 versus a price of A$0.0510, about −50% upside (overvalued).
What is the fair value of EMD?
Our model-based fair value for Emyria Ltd is A$0.0255 (as of Jun 24, 2026), built from audited fundamentals. The current price: A$0.0510.
What is the quality score of EMD?
Emyria Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Emyria Ltd (EMD)?
Our model-based price target is the fair value of A$0.0255 (as of Jun 24, 2026) from 1 valuation models. Cautious scenario A$0.0170, optimistic scenario A$0.0340. It is a calculation from audited fundamentals, not an analyst target.
What is the Emyria Ltd stock forecast for 2026?
Our models put fair value at A$0.0255, about −50% upside versus a price of A$0.0510 (overvalued). Cautious scenario A$0.0170, optimistic scenario A$0.0340. The calculation is refreshed regularly with new filings.
What is the revenue of Emyria Ltd (EMD)?
Emyria Ltd reported trailing-twelve-month revenue of about A$2.3M (latest available figure, as of Jun 24, 2026).
What is the intrinsic value of Emyria Ltd (EMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Emyria Ltd it is A$0.0255 per share (as of Jun 24, 2026), against a price of A$0.0510. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Emyria Ltd stock overvalued or undervalued in 2026?
As of Jun 24, 2026, EMD trades above its calculated fair value: price A$0.0510, fair value A$0.0255, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EMD?
No. The price is what the market pays today (A$0.0510); the fair value is what the company's own numbers justify (A$0.0255). For Emyria Ltd the two are A$0.0255 per share apart. That gap is exactly why we show both numbers side by side.
How much is Emyria Ltd worth?
The market values Emyria Ltd at about A$32.3M (market capitalisation, as of Jun 24, 2026). Per share that is A$0.0510; our models calculate a fair value of A$0.0255 per share.
What do the bullish and bearish scenarios say about EMD?
Our models span a range for Emyria Ltd: cautious scenario A$0.0170, base A$0.0255, optimistic A$0.0340 per share (as of Jun 24, 2026, price A$0.0510). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Emyria Ltd (EMD)?
Balance-sheet figures for Emyria Ltd (as of Jun 24, 2026): return on equity −58.7%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is EMD from its 52-week high?
Emyria Ltd trades at A$0.0510, about 31% below its 52-week high of A$0.0740 and 42% above the low of A$0.0360 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0255 is for.
Which stocks are comparable to Emyria Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Emyria Ltd stock attractive at the current price?
The data as of Jun 24, 2026: price A$0.0510, calculated fair value A$0.0255 (−50%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EMD calculated?
We run Emyria Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0255, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Emyria Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Emyria Ltd (EMD)?
The closing price on Sep 24, 2026 was A$0.0510. Our model-based fair value is A$0.0255, about −50% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Emyria Ltd right now?
The price sits above even our optimistic bull case (A$0.0340). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (A$0.0170 to A$0.0340) leaves room in how you read the outcome.

Key figures of Emyria Ltd

How large is the market capitalisation of Emyria Ltd (EMD)?
The market capitalisation of Emyria Ltd is A$32.3M (≈ $22.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Emyria Ltd (EMD)?
The price-to-sales ratio of Emyria Ltd is 14.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Emyria Ltd (EMD)?
Earnings per share at Emyria Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Emyria Ltd (EMD)?
The net margin of Emyria Ltd is −199% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Emyria Ltd (EMD)?
The return on equity (ROE) of Emyria Ltd is −58.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Emyria Ltd (EMD)?
On an EBIT basis the return on assets of Emyria Ltd is −80.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Emyria Ltd (EMD)?
The operating margin of Emyria Ltd is −126% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Emyria Ltd (EMD)?
Revenue at Emyria Ltd is growing +136% versus a year earlier (3y avg −8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Emyria Ltd (EMD) generate?
The free cash flow of Emyria Ltd is −A$2.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Emyria Ltd (EMD) hold?
Emyria Ltd holds more cash than debt, A$3.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Emyria Ltd in the live analysis

One click puts Emyria Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.